Why CureVac (CVAC) Stock Is Rising

Comments
Loading...
Zinger Key Points

Shares of CureVac BV CVAC are trading higher by 13.5% to $4.10 during Monday’s session following a CDC report highlighting a significant increase in acute respiratory illnesses nationwide.

The surge in healthcare visits, driven by higher cases of seasonal influenza, COVID-19 and RSV, has renewed interest in vaccine and therapeutic manufacturers during Monday’s trading session.

CureVac, a biotechnology company specializing in mRNA technology, is seen as a key player in developing next-generation vaccines. The company is advancing its mRNA platform to address not only COVID-19 but also other respiratory viruses like RSV and influenza.

CureVac's pipeline includes partnerships and clinical trials targeting these illnesses, potentially making the company well-positioned to benefit from heightened demand for respiratory virus treatments.

Read Also: Uber CFO Says Stock Undervalued, Initiates $1.5 Billion Accelerated Stock Buyback

How To Buy CVAC Stock

By now you're likely curious about how to participate in the market for CureVac – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.

In the case of CureVac, which is trading at $4.07 as of publishing time, $100 would buy you 24.57 shares of stock.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

According to data from Benzinga Pro, CVAC has a 52-week high of $5.28 and a 52-week low of $2.22.

CVAC Logo
CVACCureVac NV
$2.70-0.74%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
37.75
Growth
-
Quality
-
Value
95.37
Price Trend
Short
Medium
Long
Got Questions? Ask
Which biotech companies may surge with CVAC?
How will increased respiratory illnesses impact vaccine demand?
Are there mRNA technology stocks to watch now?
Which pharmaceutical partnerships could benefit from CVAC's pipeline?
What impact will CDC reports have on healthcare investments?
Could influenza treatments drive growth in biotech?
Who are the key competitors to CureVac in mRNA?
How might investor sentiment shift in biotech stocks?
Which therapeutic companies are poised for growth?
Is it time to explore healthcare ETFs amid rising illness rates?
Market News and Data brought to you by Benzinga APIs

Posted In: